Second line therapy for HER2 + mBC
Transcription:Andrew D. Seidman, MD: After this patient completes the taxane, trastuzumab, and pertuzumab regimen that 90% of you have chosen, , or pacli , she was kept on her trastuzumab and pertuzumab. And then after a year, then in HP…